SCHEMBL4173261

SCHEMBL4173261

COC(=O)c1c(C)nc(C)c(C(=O)OC)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
NPSR1 Q6W5P4 2/20 0.48
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 3/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 2/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
ABCG2 Q9UNQ0 1/20 0.44
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CYP3A4 P08684 1/20 0.39
ACHE P22303 1/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4173266 0.92 KMT2A (0.54) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL29157474 0.84 KDM4E (0.50) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL28828745 0.82 KDM4E (0.49) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL5506773 0.81 NPSR1 (0.48) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL23574377 0.79 NPSR1 (0.46) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL4168423 0.79 ADORA3 (0.49) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL22192888 0.77 ADORA3 (0.63) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL21032131 0.77 KDM4E (0.45) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL29157475 0.77 KMT2A (0.53) KDM4ENPSR1ALDH1A1KMT2AHPGD
SCHEMBL30843854 0.76 KDM4E (0.44) KDM4ENPSR1ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163535-A1 Substituted Heteroarylalkanoic Acids THE INSTITUES FOR PHARMACEUTICAL DISCOVERY, INC. (US) 2009-06-25 US disclosed
EP-1444228-B1 SUBSTITUTED HETEROARYLALKANOIC ACIDS AND THEIR USE AS ALDOSE REDUCTASE INHIBITORS INST FOR PHARM DISCOVERY INC (US) 2008-05-21 EP disclosed
US-7361671-B2 Substituted heteroarylalkanoic acids THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) 2008-04-22 US disclosed
US-20030166668-A1 Substituted heteroarylalkanoic acids THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. A CORPORATION OF THE STATE OF DELAWARE 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163535-A1 Substituted Heteroarylalkanoic Acids GPR119, LIPA, LIPC KDM4E 4022/4885NPSR1 1579/4885ALDH1A1 227/4885
US-20030166668-A1 Substituted heteroarylalkanoic acids GPR119, LIPA, DDC KDM4E 4051/4885NPSR1 1161/4885ALDH1A1 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.